__NUXT_JSONP__("/drugs/Idecabtagene_Vicleucel", (function(a,b,c,d,e,f){return {data:[{drug:{slug:b,emaEpar:[{activeSubstance:c,conditionIndication:"Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy.",inn:c,marketingAuthorisationDate:"2021-08-18 00:00:00",marketingAuthorisationHolder:"Celgene Europe B.V.",medicineName:d,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fabecma"}],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.",fdaUniiCode:"8PX1X7UG4D",identifier:"C117729",preferredName:e,semanticType:"Cell",subclassOf:["C129826","C176023"],synonyms:[d,"Anti-BCMA CAR T Cells BB2121","Anti-BCMA-CAR-transduced T Cells BB2121","BB2121","BCMA-specific CAR-expressing T Lymphocytes BB2121","IDECABTAGENE VICLEUCEL","Ide-cel",e]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FIdecabtagene_Vicleucel",extension:".json",createdAt:f,updatedAt:f}}],fetch:{},mutations:void 0}}("","Idecabtagene_Vicleucel","idecabtagene vicleucel","Abecma","Idecabtagene Vicleucel","2021-10-30T13:19:28.613Z")));